Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

被引：2

作者：

Dima, Danai ^{[1
]}

Hu, Xiao ^{[2
]}

Dower, Joshua ^{[2
]}

Zhang, Diana ^{[3
]}

Comenzo, Raymond ^{[4
]}

Varga, Cindy ^{[4
]}

机构：

[1] Cleveland Clin Fdn, Hematol Oncol Div, 9500 Euclid Ave, Cleveland, OH 44195 USA

[2] Tufts Med Ctr, Hematol Oncol Div, Boston, MA 02111 USA

[3] Massachusetts Gen Hosp, Internal Med Div, Boston, MA 02114 USA

[4] Tufts Med Ctr, Div Hematol Oncol, John C Davis Myeloma & Amyloid Program, Boston, MA 02111 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 05期

关键词：

AL; RESPONSES;

D O I：

10.1080/10428194.2021.2018585

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1246 / 1250

页数：5

共 19 条

[1] Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis [J].

Abeykoon, Jithma P. ;

Zanwar, Saurabh ;

Dispenzieri, Angela ;

Gertz, Morie A. ;

Leung, Nelson ;

Kourelis, Taxiarchis ;

Gonsalves, Wilson ;

Muchtar, Eli ;

Dingli, David ;

Lacy, Martha Q. ;

Hayman, Suzanne R. ;

Buadi, Francis ;

Warsame, Rahma ;

Kyle, Robert A. ;

Rajkumar, Vincent ;

Kumar, Shaji ;

Kapoor, Prashant .

LEUKEMIA, 2019, 33 (02) :531-536

[2] Organ responses with daratumumab therapy in previously treated AL amyloidosis [J].

Chung, Alfred ;

Kaufman, Gregory P. ;

Sidana, Surbhi ;

Eckhert, Erik ;

Schrier, Stanley L. ;

Lafayette, Richard A. ;

Arai, Sally ;

Witteles, Ronald M. ;

Liedtke, Michaela .

BLOOD ADVANCES, 2020, 4 (03) :458-466

[3] Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis [J].

Comenzo, R. L. ;

Reece, D. ;

Palladini, G. ;

Seldin, D. ;

Sanchorawala, V. ;

Landau, H. ;

Falk, R. ;

Wells, K. ;

Solomon, A. ;

Wechalekar, A. ;

Zonder, J. ;

Dispenzieri, A. ;

Gertz, M. ;

Streicher, H. ;

Skinner, M. ;

Kyle, R. A. ;

Merlini, G. .

LEUKEMIA, 2012, 26 (11) :2317-2325

[4] Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy [J].

Dima, Danai ;

Dower, Joshua ;

Comenzo, Raymond L. ;

Varga, Cindy .

CANCER MANAGEMENT AND RESEARCH, 2020, 12 :7891-7903

[5] AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis [J].

Dittrich, Tobias ;

Bochtler, Tilmann ;

Kimmich, Christoph ;

Becker, Natalia ;

Jauch, Anna ;

Goldschmidt, Hartmut ;

Ho, Anthony D. ;

Hegenbart, Ute ;

Schoenland, Stefan O. .

BLOOD, 2017, 130 (05) :632-642

[6] Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis [J].

Godara, Amandeep ;

Toskic, Denis ;

Albanese, Jack ;

Rosenthal, Benjamin ;

Siddiqui, Nauman S. ;

Kugelmass, Adin ;

Zhou, Ping ;

Fogaren, Teresa ;

Varga, Cindy ;

Landau, Heather J. ;

Comenzo, Raymond L. .

AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (01) :E20-E23

[7] Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis [J].

Kaufman, Gregory P. ;

Schrier, Stanley L. ;

Lafayette, Richard A. ;

Arai, Sally ;

Witteles, Ronald M. ;

Liedtke, Michaela .

BLOOD, 2017, 130 (07) :900-902

[8] Daratumumab proves safe and highly effective in AL amyloidosis [J].

Khouri, Jack ;

Kin, Andrew ;

Thapa, Bicky ;

Reu, Frederic J. ;

Bumma, Naresh ;

Samaras, Christy J. ;

Liu, Hien D. ;

Karam, Mary A. ;

Reed, Janice ;

Mathur, Saveta ;

Faiman, Beth M. ;

Devries, Georgia ;

Zonder, Jeffrey ;

Valent, Jason .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (02) :342-344

[9] Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21 [J].

Kimmich, Christoph R. ;

Terzer, Tobias ;

Benner, Axel ;

Hansen, Timon ;

Carpinteiro, Alexander ;

Dittrich, Tobias ;

Veelken, Kaya ;

Jauch, Anna ;

Huhn, Stefanie ;

Basset, Marco ;

Goldschmidt, Hartmut ;

Mueller-Tidow, Carsten ;

Schoenland, Stefan O. ;

Hegenbart, Ute .

AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) :E253-E257

[10] Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria [J].

Kimmich, Christoph R. ;

Terzer, Tobias ;

Benner, Axel ;

Dittrich, Tobias ;

Veelken, Kaya ;

Carpinteiro, Alexander ;

Hansen, Timon ;

Goldschmidt, Hartmut ;

Seckinger, Anja ;

Hose, Dirk ;

Jauch, Anna ;

Woerner, Stefan ;

Beimler, Joerg ;

Mueller-Tidow, Carsten ;

Hegenbart, Ute ;

Schoenland, Stefan O. .

BLOOD, 2020, 135 (18) :1517-1530

← 1 2 →